FDA News

FDA News – January 2017

January 2017, Vol 7, No 1 - FDA News

In This Article Rubraca Approved for Advanced Ovarian Cancer with BRCA Mutations Avastin Approved for Platinum-Sensitive Ovarian Cancer Darzalex Approved for Use in Combination with Standard Regimen for Multiple Myeloma Opdivo Now Approved for Head and Neck Squamous-Cell Carcinoma Rubraca [ Read More ]

FDA News – September 2016

September 2016, Vol 6, No 9 - FDA News

In This Article First Extended-Release Serotonin Receptor Antagonist Approved for the Prevention of CINV Keytruda Receives New Indication for Head and Neck Squamous-Cell Carcinoma Cabometyx Approved for Patients with Advanced Renal-Cell Carcinoma First Extended-Release Serotonin Receptor Antagonist Approved for the [ Read More ]

Recent Drug Approvals

February 2015, Vol 5, No 1 - FDA News

Jakafi Gets New Indication for Use in Patients with Polycythemia Vera The FDA approved ruxolitinib (Jakafi; Incyte Corporation) for the treatment of patients with polycythemia vera (PV) who have had an inadequate response to or are intolerant of hydroxyurea. The [ Read More ]

Recent Drug Approvals

November 2014, Vol 4, No 7 - FDA News

FDA Approves First Anti–PD-1: Pembrolizumab Indicated for Advanced Melanoma The FDA approved the first ­­anti–programmed death receptor-1 (PD-1) therapy, pembrolizumab (Keytruda; Merck), for patients with unresectable or metastatic melanoma and disease progression after treatment with other melanoma therapy, such as [ Read More ]